



Original Article

CFTR: New insights into structure and function and implications for modulation by small molecules[☆]

Bertrand Kleizen^{a,*}, John F. Hunt^b, Isabelle Callebaut^c, Tzyh-Chang Hwang^d,
Isabelle Sermet-Gaudelus^e, Sylvia Hafkemeyer^f, David N. Sheppard^g

^a Cellular Protein Chemistry, Department of Chemistry, Utrecht University, Utrecht, the Netherlands

^b Department of Biological Sciences, Columbia University, New York, NY, USA

^c IMPMC, Sorbonne Université, Muséum National d'Histoire Naturelle, UMR CNRS 7590, Paris, France

^d Department of Medical Pharmacology and Physiology, Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO, USA

^e INSERM U1151, Institut Necker Enfants Malades, Université Paris Descartes, Paris, France

^f Mukoviszidose Institut, Bonn, Germany

^g School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK

ARTICLE INFO

Article history:

Received 31 July 2019

Revised 17 October 2019

Accepted 18 October 2019

Available online 21 November 2019

Keywords:

Membrane protein

ABC-transporter

Mutations

F508del

Therapy

Clinical drugs

Cystic fibrosis

ABSTRACT

Structural biology and functional studies are a powerful combination to elucidate fundamental knowledge about the cystic fibrosis transmembrane conductance regulator (CFTR). Here, we discuss the latest findings, including how clinically-approved drugs restore function to mutant CFTR, leading to better clinical outcomes for people with cystic fibrosis (CF). Despite the prospect of regulatory approval of a CFTR-targeting therapy for most CF mutations, strenuous efforts are still needed to fully comprehend CFTR structure-and-function for the development of better drugs to enable people with CF to live full and active lives.

© 2019 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.

1. Background

Mutations in the Cystic Fibrosis (CF) gene alter the structure and function of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) channel, impairing the flow of chloride and bicarbonate ions across epithelia in many organs of the body [1]. CFTR shares an overall architecture that is conserved in ATP-binding cassette (ABC) transporters and consists of two transmembrane domains (TMD1 and TMD2), two nucleotide-binding domains (NBD1 and NBD2), and a unique regulatory (R)-region (Fig. 1A) [2]. The correct assembly of these individual domains into a stable, yet flexible structure facilitates conformational changes, driven by phosphorylation of the R-region and ATP-binding and hydrolysis at the NBDs, which gate the channel pore formed by the TMDs [3,4].

Combined efforts from structural biology and electrophysiology provides a comprehensive view of CFTR's structure-function relationships [3,4]. This fundamental principle of protein science is key to understanding how disease-causing mutations and clinically-approved drugs impact the local structure of CFTR, leading to long range (allosteric) conformational changes, which alter channel function. This knowledge is of interest not just to scientists, clinicians and healthcare professionals, but also to people with CF. Through patient education, therapy adherence might be increased, leading to greater clinical benefit.

Four excellent speakers (John F. Hunt [JFH], Isabelle Callebaut [IC], Tzyh-Chang Hwang [T-CH] and Isabelle Sermet-Gaudelus [IS-G]) were invited to the Pre-Conference Meeting (PCM) of the 16th ECFS Basic Science Conference (Dubrovnik, Croatia, 27–30 March 2019) to share their views on CFTR structure-and-function in health and disease, the mechanism of action of clinically-approved therapeutics targeting CFTR, their clinical benefit and future prospects. Here, we summarise the highlights from the speakers' presentations and the plenary discussions, facilitated by e-voting to engage the expertise of the audience.

[☆] This paper is part of a Supplement supported by The European Cystic Fibrosis Society (ECFS).

* corresponding author.

E-mail address: b.kleizen@uu.nl (B. Kleizen).




Fig. 1. Open and closed structures and models of CFTR (A) Schematic representation of CFTR with its characteristic ABC transporter architecture. The positions of the plasma membrane (grey) and F508 are indicated; numbers identify individual transmembrane segments. Two N-glycans are present on the fourth extracellular loop between TM7 and TM8. (B and C) Orthogonal and outside views of PyMOL representations of the cryo-EM structures of human CFTR (left: dephosphorylated [PDB id: 5UAK]; centre: phosphorylated [PDB id: 6MSM]) and 3D model of the open-channel configuration [9] with domains colour-coded according to the schematic in A. (D) Magnified view of the Ivacaftor-bound cryo-EM structure [PDB id: 6O2P] rotated 135° compared to the structures in B to highlight residues interacting with the drug in this structure [12,16]. Abbreviations: ICL, intracellular loop; NBD, nucleotide-binding domain; R, Regulatory (R)-region; TMD, transmembrane domain.

2. Recent highlights from the CFTR structure: the resolution revolution

Pioneering work which solved the first high-resolution crystal structures of an ABC transporter [5] and the first nucleotide-binding domain of CFTR [6] paved the way for the first three-dimensional molecular models of CFTR [7,8], which were improved using molecular dynamics simulations (Fig. 1B and C right) [9]. Recently, in less than three years, Jue Chen and colleagues have made a huge impact by solving cryo-EM structures of human CFTR in dephosphorylated [10], phosphorylated [11], and even drug-bound conformations [12] (Fig. 1B and C left and centre and Fig. 1D).

Comparison of the *in silico* 3D-models and the cryo-EM structures highlights a remarkable degree of similarity [9,13], which are conserved in ABC exporters, such as CFTR [14]. These include (i) the dimerization and the partial or full dissociation of the NBDs; (ii) the binding of the NBDs to two intracellular loops (ICLs), one each from TMD1 and TMD2 (Fig. 1B) and (iii) the ‘mixing’ or ‘domain-swapping’ of two transmembrane segments from one TMD with four segments from the other TMD to form two structural units, which move to gate the pore. The 3D models of CFTR have stood the test of time very well, arguing that cryo-EM and molecular dynamics simulations (together with electrophysiology) should be combined to explore CFTR’s conformational landscapes to understand its structure-and-function (Fig. 1B and C, IC, PCM).

New insights into CFTR structure-and-function emerged from the cryo-EM structures (Fig. 1B–D). These include (i) the unique conformation of CFTR’s N-terminus (lasso motif, dark blue, Fig. 1), which wraps around TM2 and TM6 of TMD1 and TM10 and TM11

of TMD2 [10]; (ii) the R-region that ‘wedges’ between the NBDs to prevent their interaction, but which moves away when phosphorylated to allow NBD dimerization and hence, channel opening [11,15]; (iii) a locally unstructured region in TM8 (TMD2), located close to the transmembrane segments that gate the channel pore [11] (IC & JFH, PCM) and (iv) a binding site for small molecule potentiators (Ivacaftor and GLPG1837), which enhance channel gating, located at the interface between the TMDs; both compounds bind the same site close to the unstructured region of TM8 [12,16] (T-CH, PCM). As summarised below, these latter two points were the subject of much discussion at the PCM.

3. TM8 leads the dance to open the channel

Comparison of the phosphorylated [11] and dephosphorylated cryo-EM structures [10] of human CFTR suggest that rigid-body rotation of the TMDs and local conformational changes at the extracellular end of TM8 and TM12 ‘toggle’ the CFTR pore between open and closed conformations. However, in the published phosphorylated structure the CFTR pore is slightly smaller than the diameter of a chloride ion, raising the possibility that this conformation does not correspond to the open channel state observed in electrophysiological experiments (Fig. 1B and C) [11]. Thus, the fully open state might be an alternative conformation not observed in the published structures nor the new cryo-EM structures of human CFTR (JFH, PCM).

To gain new insight into the molecular motions of the TMDs, particularly TM8, IC and co-workers performed molecular dynamics simulations. These simulations suggest that when TM8 ‘swings

out' to open the channel, there are coordinated movements of TM6, TM7 and TM12 (Fig. 1B and C) (IC, PCM). Of note, both TM8 and TM6 are in a balancing act between stability and flexibility (i.e. structure and function). These transmembrane segments contain charged residues essential for CFTR function at the expense of their overall hydrophobicity and stability in the bilayer, which explains why they need more assistance during CFTR synthesis to increase their stability in the bilayer [17,18]. Moreover, the CF mutation R347P in TM6, which perturbs conductance [19] requires correction by the small molecule Lumacaftor to deliver it to the plasma membrane [20]; the same is likely true for the CF mutation L927P in TM8 [21].

Interestingly, in chicken CFTR TM8 adopts a conformation much more similar to the 3D models of human CFTR than the cryo-EM structures (Fig. 1B and C) [15]. This result emphasizes the importance of the conformational dynamics of TM8. It also highlights the need for more cryo-EM structures and the value of other techniques, such as solid-state NMR [22] or single-molecule DEER (double electron-electron resonance) analysis [23] combined with conformation-specific nanobodies to stabilize a particular structure, in case cryo-EM fails to complete the picture of CFTR's dynamic landscape at atomic resolution.

4. TM8: a 'sweet spot' for a small pebble to hit the giant!

This analogy from David and Goliath was used to describe how a small molecule precisely modulates CFTR function (T-CH, PCM). The small pebbles in this story are CFTR potentiators, such as Ivacaftor [24], which has high affinity (nM range), but low efficacy and GLPG1837 [25], which has lower affinity (μM range), but higher efficacy (T-CH, PCM). Despite their structural differences, both potentiators modulate CFTR gating in a competitive manner [25], a finding consistent with the latest cryo-EM structures, which demonstrate that they share a common binding site [12,16].

Molecular modelling and cryo-EM in combination with structure-guided biochemical and electrophysiological experiments found a 'sweet spot' made mostly of hydrophobic residues involved in potentiator (Ivacaftor and GLPG1837) binding in the phosphorylated and dephosphorylated states of CFTR. Consistent with earlier data (reviewed by Wang et al. [26]), this site is embedded in the membrane at the interface between the TMDs (Fig. 1D) [12,16]. Of note, the unstructured region of TM8 is proximal to this potentiator-binding pocket [12,16]. Given the role of TM8 in gating the CFTR pore, this observation spatially links the site-of-binding and site-of-action of these small molecules [12,16].

CFTR is highly dynamic, spontaneously opening and closing in the presence of ATP once it is phosphorylated by PKA [27]. Based on its properties, a simple kinetic model of allosteric modulation explains how potentiators bind to CFTR in a state-dependent manner (T-CH, PCM). This model predicts that potentiators have

higher affinity for the open state and lower affinity for the closed state consistent with their action on gating kinetics ([25], T-CH, PCM). Because the potentiator-binding site was also found in the closed channel conformation [25], further investigation is required to elucidate how potentiator binding initiates allosteric modulation of conformational changes during CFTR channel gating. Some clues are provided by structural analyses using limited proteolysis [20] and hydrogen/deuterium exchange [28], which suggest that the N-terminus of TMD1 and ICL1, ICL2 and ICL4 may be involved.

With a potentiator-binding site determined at atomic resolution, structure-based drug design should permit the development of even better CFTR potentiators, a view shared by many scientists (Table 1). Developments in cryo-EM move fast. We therefore anticipate that the CF field will soon have structures of the small molecules from the triple-combination therapy (Tezacaftor-Elexacaftor-Ivacaftor [29]) bound to CFTR. Future structural studies should also investigate the interaction with CFTR of co-potentiators that enhance markedly the action of Ivacaftor [30].

5. Misfolding and dysfunction of the F508del-CFTR

F508del-CFTR is a textbook example of how a mutation, by causing a local folding (structural) defect in one domain (NBD1) [31,32], allosterically influences the assembly of all other CFTR domains [33], leading to an unstable protein, which is recognized by cellular protein quality control machineries and degraded (reviewed by Farinha et al. [34]). Clearly, F508del-CFTR has multiple conformational defects that impair its structure and function, even when the protein is rescued to the cell surface (reviewed by Mijnders et al. [35]). Triple-combination therapy rescues F508del-CFTR folding to ≥50% of the wild-type levels [29,36], but other drugs, maybe even NBD1 specific, might be developed to cure most conformational defects [35,36].

Can we understand the allosteric problems caused by the F508del mutation at the structural level? Does this information identify new target(s) to rescue F508del-CFTR? These are key questions addressed by the new cryo-EM structures of human F508del-CFTR (JFH, PCM). Although compensatory mutations were required to stabilise the protein to express and purify it, new insights about its conformational flexibility will emerge from classifying and resolving different structures harbouring F508del and other CF-causing mutations. More investigations are needed to understand why removal of the unstructured and flexible Regulatory Insertion from NBD1 rescues F508del-CFTR [37]. For this work, nanobodies might help to locally stabilize CFTR to uncover new conformational states as was recently demonstrated by elegant binding studies, which suggest that the dissociation of NBD1 from the TMDs is an important dynamic feature of CFTR [38].

There is clear consensus that we should understand how other frequent CF mutations impact CFTR structure-and-function

Table 1

Results of two live e-voting polls held at the PCM. The summary results provide an interesting overview of expert opinions about important considerations and future directions for the CF community.

| Session 1 (n = 49) | | | | |
|---|---------|---------|-------|----------------|
| Does structural insight lead to better CFTR modulators? | 89% yes | 11% no | | |
| Can we do structure-based drug design on CFTR? | 60% yes | 17% no | | 23% no opinion |
| How many druggable sites does CFTR have? | 60% ≥6 | 11% 4–5 | 6% ≤3 | 23% no opinion |
| Should we understand the structural defects of other CF mutations? | 81% yes | 4% no | | 15% no opinion |
| Session 2 (n = 47) | | | | |
| Will the triple-combo treatments cure CF? | 14% yes | 82% no | | 6% no opinion |
| Should we keep investing in mutation-specific therapies? | 88% yes | 6% no | | 6% no opinion |
| Can we expect adverse effects with life-long CF modulator treatments? | 39% yes | 53% no | | 8% no opinion |
| Will we still have an ECFS Basic Science meeting in 2025? | 88% yes | 4% no | | 8% no opinion |

Table 2

Clinically-approved CFTR modulators.

This table presents all the clinically-approved substances at the time of publication, their product names and dosages, approval dates and patient ages, types of CF mutations, and the names of the clinical trials. References to clinical trials and guidelines and reviews on CF modulator studies, patient registry analyses, and real-life data on CFTR modulators are provided in the extended version of the table (Table S1).

| Substance | Product name | Approval date (EU & US) | Mutations | Approval Age | (Phase) Clinical trial (wks of study) |
|--|---|--|---|------------------------------------|--|
| Ivacaftor (VX-770) | Kalydeco (pill, 150 mg iva) | EU: July 2012 US: Jan 2012 | G551D | > 12 years > 6–12 years (25 kg) | (3) STRIVE (3) ENVISION (3) PERSIST (extension from STRIVE and ENVISION) |
| Ivacaftor (VX-770) | Kalydeco (pill, 150 mg iva) | EU: July 2014 US: Feb 2014 | G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D | > 6 years | (3) KONNECTION |
| Ivacaftor (VX-770) | Kalydeco (pill, 150 mg iva) | EU: Nov 2015 US: Dec 2014 | R117H heterozygotes | > 18 years (EU) > 6 years (US) | (3) KONDUCT |
| Ivacaftor (VX-770) | Kalydeco (granules 50 & 75 mg iva) | EU: Nov 2015 US: Mar 2015 | G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D | 2–5 years | (3) KIWI (24 wks) (3) KLIMB (84 wks) |
| Ivacaftor (VX-770) | Kalydeco (granules 50 & 75 mg iva) | EU: Nov 2018 US: Aug 2018 | G551D, R117H, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D | 12–24 months | (3) ARRIVAL |
| Ivacaftor (VX-770) | Kalydeco (granules 25 & 50 & 75 mg iva) | EU: not yet appr. US: Apr 2019 | G551D, R117H, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, G1349D | > 6 months | (3) ARRIVAL (not published) |
| Lumacaftor / Ivacaftor (VX-809 / VX-770) | Orkambi (pill 200 mg lum / 125 mg iva) | EU: Nov 2015 US: Jul 2015 | F508del homozygotes | > 12 years | (3) TRAFFIC, TRANSPORT (24 wks) (3) PROGRESS (96 wks) |
| Lumacaftor / Ivacaftor (VX-809 / VX-770) | Orkambi (pill 100 mg lum / 125 mg iva) | EU: Jan 2018 US: Sep 2016 | F508del homozygotes | 6–11 years | (3) VX15-809-109 (24 wks) |
| Lumacaftor / Ivacaftor (VX-809 / VX-770) | Orkambi (granules 100 mg lum / 125 mg iva & 150 mg lum / 188 mg iva) | EU: Jan 2019 US: Aug 2018 | F508del homozygotes | 2–5 years | (2) VX16-809-121 (still recruiting) |
| Tezacaftor / Ivacaftor (VX-661 / VX-770) | (EU) Symkevi (US) Symdeko (pill 100 mg teza / 150 mg iva) | EU: Nov 2018 (only the F508del heterozygous with mutations with residual function in bold) US: Feb 2018 | F508del homozygotes or F508del heterozygotes with E56K, P67L , R74W, D110E, D110H, R117C , E193K, L206W , 711+3A→G , R347H, R352Q , A455E , D579G , E831X, 2789+5G→A , S945L , S977F , F1052V, K1060T, A1067T, R1070W , F1074L, 3272-26A→G , D1152H , D1270N, 3849+10kbc→T | > 12 years | (3) EVOLVE (F508del homozygous, 24 wks) (3) EXPAND (F508del heterozygous, 24 wks) |
| Tezacaftor / Ivacaftor (VX-661 / VX-770) | (US) Symdeko (pill 50 mg teza / 75 mg iva, < 25 kg and 50 mg teza / 150 mg iva, > 25 kg) | US: Jun 2019 | F508del homozygotes or F508del heterozygotes and mutation with residual function as approved for >12 years (see above) | 6–11 years | (3) VX15-661-113 (24 wks) |
| Elexacaftor / Tezacaftor / Ivacaftor (VX-445 / VX-661 / VX-770) | Trikafta (pill 100 mg elexa / 50 mg teza / 75 mg iva) | EU: expected 2020 US: Oct 2019 | US: Patients with at least one F508del mutation | > 12 years | (2) VX445+Tez+Iva (3) VX445+Tez+Iva (F508del heterozygous with minimal function, 24 wks) (3) VX445+Tez+Iva (F508del homozygous, 4 wks) |

(Table 1). This is especially the case for CF mutations unresponsive to current correctors (e.g. N1303K [39]). Mutation-specific high-throughput screens are required to identify new CFTR modulators [30], but at the same time, it is important to identify all the drugable sites in CFTR (Table 1). This raises an important question – is there a limit to how much mutant CFTR can be corrected and stabilised? Increasing the number of suppressor mutations in wild-type CFTR enhanced protein stability, but concomitantly reduced channel activity [40]. These data highlight a tug-of-war between stability and flexibility with important consequences for how much we can correct mutant CFTR.

6. The clinical benefit of allosteric modulation of CFTR function

With CFTR modulators approved for use in the clinic (for overview, see Table 2 and Table S1), we can investigate whether the allosteric correction of CFTR function has clinical benefit for people with CF. This question is best addressed with Ivacaftor (Kalydeco), which has now been administered to individuals with CFTR gating mutations for more than seven years [41]. Robust Ivacaftor-induced improvements in ion transport, airway surface liquid height and ciliary beating in vitro by cultured human

bronchial epithelial cells correlated well with clinical parameters, including reduced sweat chloride concentration, improved lung function (measured by forced expiratory volume in one second; FEV₁), increased mucus clearance and reduced lung inflammation and exacerbations [42] (IS-G, PCM). Clearly, targeting the cause of CF relieves clinical manifestations. Yet, a small pilot study of twelve Ivacaftor-treated patients followed for 2 years showed an unexpected increase in *Pseudomonas aeruginosa* infection after an initial decline [43], which might reflect disease progression despite Ivacaftor treatment [44].

'Real-world' Ivacaftor data provide much greater insight into how clinically-approved drugs actually impact the lives of people with CF [45] (IS-G, PCM). This is even more important for Ivacaftor-Lumacaftor combination therapy (Orkambi), which showed positive results in vitro, but only modest clinical benefit [46,47]. Meta-analysis of 1700 homozygote F508del patients revealed a small increase in FEV₁ of 2.8-fold over placebo, but 2.7-fold more adverse events, leading to discontinuation of the treatment [48]. These data emphasize the need to find better drugs, which are on their way to the clinic. But, they also highlight the necessity to (i) find better cell models to correlate in vitro responses to clinical outcomes [49]; (ii) identify new biomarkers to better predict clinical outcome (e.g. bicarbonate secretion, microbiome analysis, mucus rheology and the analysis of other organs beyond the lungs [50] and (iii) discover exogenic markers to identify high- and non-responding individuals (e.g. the complex allele F87L-I1027T-F508del, which is unresponsive to Lumacaftor [51]). Intensified efforts in all these directions are needed to increase our understanding of how allosteric CFTR modulation in the larger CF population improves clinical parameters. This is especially important for life-long personalized treatment of CF.

7. The future for CF is bright, but we should not let our guard down!

A game-changer in CF treatment is the recent launch of the Trikafta triple-combination therapy for all individuals heterozygous for F508del (Table 2 and Table S1) (Vertex press release: <https://investors.vrtx.com/news-releases/news-release-details/adding-multimedia-fda-approves-trikafta>). This treatment shows a remarkable in vitro increase in F508del-CFTR function up to 85% of wild-type and in vivo lung function of about 14% (FEV₁) [29,36]. In theory, this triple-combination therapy should improve CFTR function in individuals homozygous for F508del above that of a non-disease heterozygous CF carrier with 50% normal CFTR function. However, time will tell whether theory meets practice, and above all, whether this treatment has sufficient clinical benefit in heterozygous F508del patients carrying a poorly responding (e.g. N1303K, [39]) or non-responding mutation (e.g. premature termination codon mutations) on the other allele.

Life-long daily drug treatment with combinations of CFTR modulators is recognised to be an important issue (IS-G, PCM). Moreover, studies of CF ferrets with the G551D mutation administered with Ivacaftor suggest that newborns with CF or even pregnant women carrying CF fetuses should be treated to prevent early organ damage, especially of the pancreas [52]. However, caution is urged because of the possibility of unpredictable long-term adverse effects (Table 1). Moreover, there might be differential responses to CFTR modulators because of yet unclear mechanisms [51,53]. Therefore, we need more drugs on the 'shelf' to secure life-long CF treatments. We certainly should not let our guard down and stop all discovery pipelines now that the triple-combination treatment [29] has entered the clinic.

Will the triple-combination therapy fully cure CF (Table 1)? Perhaps at some point in the future gene-repair using CRISPR/Cas9 or mRNA-directed antisense oligonucleotide strategies will tackle

the disease directly at the level of the faulty gene or its transcribed product [54], sweeping away the above-mentioned concerns. But, before we can safely and precisely target the CF gene, while upholding all ethical standards, we depend on the success of small molecule treatments and improved knowledge of CFTR structure-function relationships to identify new therapeutic opportunities. Thus, this is the important direction we should take at least until the 2025 ECFS Basic Science Conference (Table 1).

Author contributions

BK wrote the commentary, which the other authors revised critically for important intellectual content. SH made the overview of clinical studies shown in Table 2 and Table S1. All authors approved the final version of the commentary.

Declaration of Competing Interest

DNS is the recipient of a Vertex Innovation Award, IS-G is the recipient of two Vertex Innovation Awards and a member of the scientific boards of Eloxx, PTC Therapeutics and Vertex Therapeutics. T-CH has an ongoing service agreement with Abbvie and a sponsored research grant from Nanova.

Acknowledgements

We thank the ECFS and the CF patient organizations from Belgium, France, Germany, Italy, the Netherlands and the UK for supporting the PCM. We are very grateful to laboratory colleagues for valuable discussions. Work in the authors' laboratories was supported by The Dutch Cystic Fibrosis Foundation, NCFS (BK), The Netherlands Organization for Scientific Research (NWO, grant no. 731.017.420) (BK), Cystic Fibrosis Foundation Therapeutics (CFTR 3D Structure Consortium, J Frank, J Kappes and JFH), The French Association Vaincre La Mucoviscidose (IC), GENCI-[CINES] (grant no. 2018-A0040707206 and 2019-A0060707206) (IC), The National Institutes of Health (grant no. NIHR01DK55835) (T-CH), The French Association Vaincre La Mucoviscidose, Cystic Fibrosis Foundation, Agence Nationale pour la Recherche, Programme Hospitalier de Recherche Clinique (IS-G), Cystic Fibrosis Foundation Therapeutics grant no. (SHEPPA14XX0) (DNS), Cystic Fibrosis Trust grant no. (SRC005/SRC011) (DNS) and the Medical Research Council grant no. (MR/S00274X/1) (DNS).

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jcf.2019.10.021.

References

- [1] Cutting GR. Cystic fibrosis genetics: from molecular understanding to clinical application. *Nat Rev Genet* 2015;16:45–56. doi:10.1038/nrg3849.
- [2] Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science* 1989;245:1066–73. doi:10.1126/science.2475911.
- [3] Csanády L, Vergani P, Gadsby DC. Structure, gating, and regulation of the CFTR anion channel. *Physiol Rev* 2019;99:707–38. doi:10.1152/physrev.00007.2018.
- [4] Hwang T-C, Yeh J-T, Zhang J, Yu Y-C, Yeh H-I, Destefano S. Structural mechanisms of CFTR function and dysfunction. *J Gen Physiol* 2018;150:539–70. doi:10.1085/jgp.201711946.
- [5] Dawson RJP, Locher KP. Structure of a bacterial multidrug ABC transporter. *Nature* 2006;443:180–5. doi:10.1038/nature05155.
- [6] Lewis HA, Buchanan SG, Burley SK, Connors K, Dickey M, Dorwart M, et al. Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. *EMBO J* 2004;23:282–93. doi:10.1038/sj.emboj.7600040.
- [7] Serohijos AWR, Hegedüs T, Aleksandrov AA, He L, Cui L, Dokholyan NV, et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. *Proc Natl Acad Sci USA* 2008;105:3256–61. doi:10.1073/pnas.0800254105.

- [8] Mornon JP, Lehn P, Callebaut I. Atomic model of human cystic fibrosis transmembrane conductance regulator: membrane-spanning domains and coupling interfaces. *Cell Mol Life Sci* 2008;65:2594–612. doi:10.1007/s00018-008-8249-1.
- [9] Hoffmann B, Elbahnsi A, Lehn P, Décout J-L, Pietrucci F, Mornon J-P, et al. Combining theoretical and experimental data to decipher CFTR 3D structures and functions. *Cell Mol Life Sci* 2018;75:3829–55. doi:10.1007/s00018-018-2835-7.
- [10] Liu F, Zhang Z, Csanády L, Gadsby DC, Chen J. Molecular structure of the human CFTR ion channel. *Cell* 2017;169:85–8. doi:10.1016/j.cell.2017.02.024.
- [11] Zhang Z, Liu F, Chen J. Molecular structure of the ATP-bound, phosphorylated human CFTR. *Proc Natl Acad Sci USA* 2018;115:12757–62. doi:10.1073/pnas.1815287115.
- [12] Liu F, Zhang Z, Levit A, Levring J, Touhara KK, Shoichet BK, et al. Structural identification of a hotspot on CFTR for potentiation. *Science* 2019;364:1184–8. doi:10.1126/science.aaw7611.
- [13] Simhaev L, McCarty NA, Ford RC, Senderowitz H. Molecular dynamics flexible fitting simulations identify new models of the closed state of the cystic fibrosis transmembrane conductance regulator protein. *J Chem Inf Model* 2017;57:1932–46. doi:10.1021/acs.jcim.7b00091.
- [14] Locher KP. Mechanistic diversity in ATP-binding cassette (ABC) transporters. *Nat Struct Mol Biol* 2016;23:487–93. doi:10.1038/nsmb.3216.
- [15] Fay JF, Aleksandrov LA, Jensen TJ, Cui LL, Kousouros JN, He L, et al. Cryo-EM visualization of an active high open probability CFTR anion channel. *Biochemistry* 2018;57:6234–46. doi:10.1021/acs.biochem.8b00763.
- [16] Yeh H-I, Qiu L, Sohma Y, Conrath K, Zou X, Hwang T-C. Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770. *J Gen Physiol* 2019;151:912–28. doi:10.1085/jgp.201912360.
- [17] Pitonzo D, Yang Z, Matsumura Y, Johnson AE, Skach WR. Sequence-specific retention and regulated integration of a nascent membrane protein by the endoplasmic reticulum Sec61 translocon. *Mol Biol Cell* 2009;20:685–98. doi:10.1091/mbc.E08-09-0902.
- [18] Tector M, Hartl FU. An unstable transmembrane segment in the cystic fibrosis transmembrane conductance regulator. *EMBO J* 1999;18:6290–8. doi:10.1093/emboj/18.22.6290.
- [19] Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ. Mutations in CFTR associated with mild-disease-form Cl^- channels with altered pore properties. *Nature* 1993;362:160–4. doi:10.1038/362160a0.
- [20] van Willigen M, Vonk AM, Yeoh HY, Kruisselbrink E, Kleizen B, van der Ent CK, et al. Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants. *Life Sci Alliance* 2019;2:e201800172. doi:10.26508/lsa.201800172.
- [21] Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. *J Cyst Fibros* 2014;13:29–36. doi:10.1016/j.jcf.2013.06.008.
- [22] Kaplan M, Narasimhan S, de Heus C, Mance D, van Doorn S, Houben K, et al. EGFR dynamics change during activation in native membranes as revealed by NMR. *Cell* 2016;167:1241–51 e11. doi:10.1016/j.cell.2016.10.038.
- [23] Hutter CAJ, Timachi MH, Hürlimann LM, Zimmermann I, Egloff P, Göddeke H, et al. The extracellular gate shapes the energy profile of an ABC exporter. *Nat Commun* 2019;10:2260. doi:10.1038/s41467-019-09892-6.
- [24] Van Goor F, Hadida S, Grootenhuys PDJ, Burton B, Cao D, Neuberger T, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. *Proc Natl Acad Sci USA* 2009;106:18825–30. doi:10.1073/pnas.0904709106.
- [25] Yeh H-I, Sohma Y, Conrath K, Hwang T-C. A common mechanism for CFTR potentiators. *J Gen Physiol* 2017;149:1105–18. doi:10.1085/jgp.201711886.
- [26] Wang Y, Cai Z, Gosling M, Sheppard DN. Potentiation of the cystic fibrosis transmembrane conductance regulator Cl^- channel by ivacaftor is temperature independent. *Am J Physiol Lung Cell Mol Physiol* 2018;315:L846–57. doi:10.1152/ajplung.00235.2018.
- [27] Hwang T-C, Sheppard DN. Gating of the CFTR Cl^- channel by ATP-driven nucleotide-binding domain dimerisation. *J Physiol (Lond)* 2009;587:2151–61. doi:10.1113/jphysiol.2009.171595.
- [28] Byrnes LJ, Xu Y, Qiu X, Hall JD, West GM. Sites associated with Kalydeco binding on human Cystic Fibrosis transmembrane conductance regulator revealed by hydrogen/deuterium exchange. *Sci Rep* 2018;8:4664. doi:10.1038/s41598-018-22959-6.
- [29] Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, et al. VX-445-Tezacaftor-ivacaftor in patients with Cystic Fibrosis and one or two Phe508del alleles. *N Engl J Med* 2018;379:1612–20. doi:10.1056/NEJMoa1807120.
- [30] Phuan P-W, Son J-H, Tan J-A, Li C, Musante I, Zlock L, et al. Combination potentiator (“co-potentiator”) therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators. *J Cyst Fibros* 2018;17:595–606. doi:10.1016/j.jcf.2018.05.010.
- [31] Hoelen H, Kleizen B, Schmidt A, Richardson J, Charitou P, Thomas PJ, et al. The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain. *PLoS One* 2010;5:e15458. doi:10.1371/journal.pone.0015458.
- [32] Wang C, Aleksandrov AA, Yang Z, Forouhar F, Proctor EA, Kota P, et al. Ligand binding to a remote site thermodynamically corrects the F508del mutation in the human cystic fibrosis transmembrane conductance regulator. *J Biol Chem* 2018;293:17685–704. doi:10.1074/jbc.RA117.000819.
- [33] Du K, Lukacs GL. Cooperative assembly and misfolding of CFTR domains in vivo. *Mol Biol Cell* 2009;20:1903–15. doi:10.1091/mbc.E08-09-0950.
- [34] Farinha CM, Matos P, Amaral MD. Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi. *FEBS J* 2013;280:4396–406. doi:10.1111/febs.12392.
- [35] Mijnders M, Kleizen B, Braakman I. Correcting CFTR folding defects by small-molecule correctors to cure cystic fibrosis. *Curr Opin Pharmacol* 2017;34:83–90. doi:10.1016/j.coph.2017.09.014.
- [36] Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, et al. VX-659-Tezacaftor-ivacaftor in patients with Cystic Fibrosis and one or two Phe508del alleles. *N Engl J Med* 2018;379:1599–611. doi:10.1056/NEJMoa1807119.
- [37] Aleksandrov AA, Kota P, Aleksandrov LA, He L, Jensen T, Cui L, et al. Regulatory insertion removal restores maturation, stability and function of ΔF508 CFTR. *J Mol Biol* 2010;401:194–210. doi:10.1016/j.jmb.2010.06.019.
- [38] Sigoillot M, Overtus M, Grodecka M, Scholl D, Garcia-Pino A, Laeremans T, et al. Domain-interface dynamics of CFTR revealed by stabilizing nanobodies. *Nature Comm* 2019;10:2636. doi:10.1038/s41467-019-10714-y.
- [39] Han ST, Rab A, Pellicore MJ, Davis EF, McCague AF, Evans TA, et al. Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators. *JCI Insight* 2018;3:e121159. doi:10.1172/jci.insight.121159.
- [40] He L, Aleksandrov AA, An J, Cui L, Yang Z, Brouillette CG, et al. Restoration of NBD1 thermal stability is necessary and sufficient to correct ΔF508 CFTR folding and assembly. *J Mol Biol* 2015;427:106–20. doi:10.1016/j.jmb.2014.07.026.
- [41] Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* 2011;365:1663–72. doi:10.1056/NEJMoa1105185.
- [42] Skilton M, Krishan A, Patel S, Sinha IP, Southern KW. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. *Cochrane Database Syst Rev* 2019;1:CD009841. doi:10.1002/14651858.CD009841.pub3.
- [43] Hisert KB, Heltshe SL, Pope C, Jorth P, Wu X, Edwards RM, et al. Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections. *Am J Respir Crit Care Med* 2017;195:1617–28. doi:10.1164/rccm.201609-1954OC.
- [44] Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C, et al. Disease progression in patients with cystic fibrosis treated with ivacaftor: data from national US and UK registries. *J Cyst Fibros* 2019. doi:10.1016/j.jcf.2019.05.015.
- [45] Kirwan L, Fletcher G, Harrington M, Jeleniewska P, Zhou S, Casserly B, et al. Longitudinal trends in real-world outcomes after initiation of ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland. *Ann Am Thorac Soc* 2019;16:209–16. doi:10.1513/AnnalsATS.201802-1490C.
- [46] Van Goor F, Hadida S, Grootenhuys PDJ, Burton B, Stack JH, Straley KS, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. *Proc Natl Acad Sci USA* 2011;108:18843–8. doi:10.1073/pnas.1105787108.
- [47] Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. Lumacaftor-ivacaftor in patients with Cystic Fibrosis homozygous for Phe508del CFTR. *N Engl J Med* 2015;373:220–31. doi:10.1056/NEJMoa1409547.
- [48] Wu H-X, Zhu M, Xiong X-F, Wei J, Zhuo K-Q, Cheng D-Y. Efficacy and safety of CFTR corrector and potentiator combination therapy in patients with Cystic Fibrosis for the F508del-CFTR homozygous mutation: a systematic review and meta-analysis. *Adv Ther* 2019;36:451–61. doi:10.1007/s12325-018-0860-4.
- [49] Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttinger L, Klay D, et al. Long-term expanding human airway organoids for disease modeling. *EMBO J* 2019;38:e100300. doi:10.15252/emboj.2018100300.
- [50] Davies JC, Drevinek P, Elborn JS, Kerem E, Lee T, et al. Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery. *J Cyst Fibros* 2019;18:677–84. doi:10.1016/j.jcf.2019.06.011.
- [51] Masson A, Schneider-Futschik EK, Baatallah N, Nguyen-Khoa T, Girodon E, Hatton A, et al. Predictive factors for lumacaftor/ivacaftor clinical response. *J Cyst Fibros* 2019;18:368–74. doi:10.1016/j.jcf.2018.12.011.
- [52] Sun X, Yi Y, Yan Z, Rosen BH, Liang B, Winter MC, et al. In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. *Sci Transl Med* 2019;11:eaau7531. doi:10.1126/scitranslmed.aau7531.
- [53] Pranke I, Hatton A, Masson A, Flament T, Le Bourgeois M, Chedevergne F, et al. Might brushed nasal cells be a surrogate for CFTR modulator clinical response? *Am J Respir Crit Care Med* 2019;199:123–6. doi:10.1164/rccm.201808-1436LE.
- [54] Pranke I, Golec A, Hinzpeter A, Edelman A, Sermet-Gaudelus I. Emerging therapeutic approaches for Cystic Fibrosis. From gene editing to personalized medicine. *Front Pharmacol* 2019;10:121. doi:10.3389/fphar.2019.00121.